Multiple myeloma (MM) is a kind of hematological malignant tumors characterized by the unnormal proliferation of plasma cell in the bone marrow, which often occurs in elderly patients and has an obvious increase of incidence. The treatment of MM has made a great progress in the 21st century. Furthermore, with the addition of effective therapies and wide application of remissive treatment combination, the therapeutic goal of MM needs to be reevaluated. Minimal residual disease (MRD) negative status has become increasingly important, and some even consider it as the primary endpoint for therapy.